Helicobacter pylori (H. pylori) infection is an established cause of gastric cancer, but whether its carcinogenic influence extends to the colorectum remains uncertain. Previous observational studies have suggested an association with colorectal cancer (CRC), although evidence that eradication might modify this risk has been limited. Han and colleagues addressed this question using long-term data from two randomized trial cohorts in Linqu County, China: the Shandong Intervention Trial (SIT; n=3,365) and the Mass Intervention Trial (MITS; n=180,284), with follow-up extending to 29.4 and 13.8 years, respectively. A nested case-cohort analysis within MITS additionally examined bacterial virulence factors and host genetic susceptibility.
Untreated H. pylori-positive individuals had a higher risk of CRC than uninfected individuals in both cohorts (SIT: HR 2.96; MITS: HR 1.27). In SIT, anti-H. pylori treatment was associated with a 53% reduction in CRC risk (HR 0.47), with an even greater reduction following successful eradication (HR 0.38). In contrast, no overall protective effect of treatment was demonstrated in MITS. However, treatment appeared beneficial among participants at high polygenic risk and among those infected with strains expressing particular H. pylori antigens. These findings raise the intriguing possibility that the consequences of H. pylori infection—and perhaps the benefits of eradication—may extend beyond the stomach and may differ according to bacterial and host characteristics.
This study is notable for its exceptionally large population, long duration of follow-up, and the opportunity to examine treatment, bacterial virulence, and host genetic susceptibility within two well-characterized trial cohorts. The consistency of the association between untreated H. pylori infection and CRC across both cohorts strengthens the signal. Equally important, however, is the inconsistency in treatment effect: eradication was associated with substantially lower CRC risk in SIT but produced no overall reduction in MITS. These analyses were also post hoc and observational within randomized trial cohorts, rather than randomized trials specifically designed to test CRC prevention.
The findings are nevertheless potentially important on a global scale. H. pylori remains highly prevalent worldwide, particularly in many regions where both infection-related disease and access to CRC screening present major public-health challenges. If eradication confers protection against CRC in selected populations, an intervention already undertaken for prevention of gastric disease could have an additional long-term benefit. However, these data are not sufficient to advocate eradication specifically for CRC prevention. The study population was geographically concentrated in China, and differences in bacterial strains, host genetics, diet, and background CRC risk may limit generalizability.
Replication in diverse populations is therefore essential. Future work should determine whether specific bacterial virulence profiles or host genetic characteristics reliably identify people most likely to gain colorectal protection from eradication. For now, the study adds an unexpected new dimension to an old pathogen: the impact of H. pylori may extend considerably further down the gastrointestinal tract than previously appreciated.
Han X, Xu H-M, Liu Z-C, et al. Helicobacter pylori infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials. Gut. Published online June 30, 2026. doi:10.1136/gutjnl-2026-338156.